



**The Clatterbridge  
Cancer Centre**  
NHS Foundation Trust

Clatterbridge Road  
Bebington  
Wirral  
CH63 4JY

Tel: 0151 556 5000  
Web: [www.clatterbridgecc.nhs.uk](http://www.clatterbridgecc.nhs.uk)

Date: 17<sup>th</sup> November 2017

**Re: Freedom of Information Request**  
**Ref: 187-2017**

Thank you for your email dated 25th October 2017 requesting information regarding Urothelial Cell Cancer.

**Please find the information required in Appendix 1.**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

**<https://www.surveymonkey.co.uk/r/H39RFMM>**

## Appendix 1

### FOI Request re Urothelial Cancer Patients

How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:

Patient Type	Total number of patients (treated and not treated)	Number currently treated with any active anti-cancer drug treatment (excl. surgery/radiotherapy only)	Number not treated (with any active anti-cancer drug treatment) NB – These patients may have received Radiotherapy or Surgery
All Urothelial cancer (UCC, transitional carcinoma, TCC) patients <b>diagnosed between April-Sept 17</b>	64	25	39
Metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients <b>(defined by using your criteria below)</b>	20	9	11

Of the metastatic\* or locally advanced\* Urothelial cancer (UCC, transitional carcinoma, TCC) patients, please state the number of patients currently being treated with the following therapies:

Therapy	Number of metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients currently treated
Cisplatinium single agent	-
Cisplatinium in combination with another agent	4
Carboplatinium single agent	-
Carboplatinium in combination with another agent	4
Any other chemo regimen without cisplatinium or carboplatinium	1
Pembrolizumab (Keytruda)	-
Atezolizumab (Tecentriq)	-

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust patients are referred:

\*TNM staging for metastatic Urothelial Cancer = Any T, any N, M1

\*TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0